We next examined the extent to which persistent abnormalities in the CD4/CD8 ratio were associated with later vs. earlier initiation of ART using the described OPTIONS cohort of recently infected adults who started therapy during the first six months of their infection (early ART) or after two years of untreated infection (later ART) (see Table S5) [37]. This evidence concerns the gene CD8A and infection.